First-in-human (FIH) phase I dose escalation study (Part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in Uveal Melanoma (Part B)

Anna Maria Di Giacomo, Federica Santangelo, Giovanni Amato, Elena Simonetti, Jill Graham, Michael M. F. Lahn, Giusy Di Conza, Tracey Hammett, Rebeca Zorrilla, Marco Durini, Ziyang Tan, Lakshmikanth Tadepally, Petter Brodin, Mariaelena Occhipinti, Matteo Simonelli, Carmelo Carlo-Stella, Armando Santoro,
Pavlina Spiliopoulou, T.R. Jeffry Evans, Michele Maio